Burgundy Asset Management’s Novartis NVS Stock Holding History

Burgundy Asset Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-8,995	Closed	-$685K	–	120
2014 Q1	$685K	Hold	8,995	–	–	0.01%	99
2013 Q4	$648K	Hold	8,995	–	–	0.01%	100
2013 Q3	$618K	Hold	8,995	–	–	0.01%	97
2013 Q2	$570K	Buy	+8,995	New	+$585K	0.01%	103

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Burgundy Asset Management's NVS Position: Q2 2014 in Review

Burgundy Asset Management sold out of Novartis (NVS) in Q2 2014, closing a stake of 8,995 shares — an estimated $685K sold.

Burgundy Asset Management first reported a position in NVS in Q2 2013 and held it in 4 quarters. The position peaked at $685K in Q1 2014. 848 funds tracked by Wall St. Rank hold NVS as of Q2 2014.

Burgundy Asset Management reported no remaining Novartis position as of Q2 2014 after selling out during the quarter.
Burgundy Asset Management sold 8,995 Novartis shares in Q2 2014, an estimated $685K.
Burgundy Asset Management first reported a position in Novartis in Q2 2013 and held it in 4 quarters.
Burgundy Asset Management's Novartis position peaked at $685K in Q1 2014.
848 funds tracked by Wall St. Rank held Novartis as of Q2 2014.

Based on Burgundy Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.